The team at Cellogen Therapeutics has tried to come up with innovative gene editing approaches to cure beta hemoglobinopathies (Transfusion dependent thalassemia and Sickle cell disease). The team has developed one stop gene editing solution’ to keep both these disorders by one gene editing approach.